JP2025516294A5 - - Google Patents
Info
- Publication number
- JP2025516294A5 JP2025516294A5 JP2024564785A JP2024564785A JP2025516294A5 JP 2025516294 A5 JP2025516294 A5 JP 2025516294A5 JP 2024564785 A JP2024564785 A JP 2024564785A JP 2024564785 A JP2024564785 A JP 2024564785A JP 2025516294 A5 JP2025516294 A5 JP 2025516294A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- sequence
- human
- dna
- dnmt3a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263337167P | 2022-05-01 | 2022-05-01 | |
| US202263337164P | 2022-05-01 | 2022-05-01 | |
| US63/337,167 | 2022-05-01 | ||
| US63/337,164 | 2022-05-01 | ||
| US202263355083P | 2022-06-23 | 2022-06-23 | |
| US63/355,083 | 2022-06-23 | ||
| PCT/US2023/066436 WO2023215711A1 (en) | 2022-05-01 | 2023-05-01 | Compositions and methods for epigenetic regulation of pcsk9 expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516294A JP2025516294A (ja) | 2025-05-27 |
| JP2025516294A5 true JP2025516294A5 (cg-RX-API-DMAC7.html) | 2026-05-11 |
Family
ID=86732155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024564785A Pending JP2025516294A (ja) | 2022-05-01 | 2023-05-01 | Pcsk9発現のエピジェネティック調節のための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4519293A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025516294A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250060954A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119836432A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023265968A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3251776A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316722A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024013483A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215711A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311610A (en) | 2021-09-21 | 2024-05-01 | Scribe Therapeutics Inc | Engineered CASX suppressor systems |
| CN119998446A (zh) | 2022-06-07 | 2025-05-13 | 斯克里贝治疗公司 | 用于靶向pcsk9的组合物和方法 |
| CA3260237A1 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression |
| EP4590820A2 (en) * | 2022-09-22 | 2025-07-30 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease |
| JP2026523341A (ja) | 2023-05-15 | 2026-07-14 | エヌクロマ・バイオ,インコーポレーテッド | Hbv遺伝子発現のエピジェネティック調節のための組成物および方法 |
| WO2024238723A1 (en) * | 2023-05-16 | 2024-11-21 | Omega Therapeutics, Inc. | Methods and compositions for modulating pcsk9 expression |
| EP4735603A2 (en) * | 2023-06-30 | 2026-05-06 | nChroma Bio, Inc. | Guide rna compositions |
| WO2025106739A1 (en) * | 2023-11-14 | 2025-05-22 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of htt expression |
| WO2025137650A2 (en) * | 2023-12-21 | 2025-06-26 | Nchroma Bio, Inc. | Compositions and methods for epigenetic editing |
| WO2025160155A1 (en) * | 2024-01-22 | 2025-07-31 | The Broad Institute, Inc. | Epigenetic targeting of prion diseases |
| WO2025167914A1 (zh) * | 2024-02-07 | 2025-08-14 | 益杰立科新加坡有限公司 | 通过表观编辑多靶点治疗疾病的方法 |
| TW202617754A (zh) * | 2024-06-21 | 2026-05-01 | 大陸商益杰立科(上海)生物科技有限公司 | 靶向b型肝炎病毒基因的工程化基因轉錄阻抑工具及其用途 |
| CN122295445A (zh) * | 2024-06-21 | 2026-06-26 | 益杰立科(上海)生物科技有限公司 | 通过表观编辑靶向调节pcsk9的方法及其用途 |
| TW202617755A (zh) * | 2024-06-21 | 2026-05-01 | 大陸商益杰立科(上海)生物科技有限公司 | 靶向pcsk9的工程化基因轉錄阻抑工具及其用途 |
| WO2025261473A1 (zh) * | 2024-06-21 | 2025-12-26 | 益杰立科(上海)生物科技有限公司 | 工程化基因转录阻抑工具及其用途 |
| WO2026064753A1 (en) | 2024-09-23 | 2026-03-26 | Tune Therapeutics, Inc. | Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing |
| WO2026158158A1 (zh) * | 2025-01-23 | 2026-07-30 | 锐正基因(苏州)有限公司 | 一种向导rna、其组合物及其在编辑pcsk9基因中的应用 |
| WO2026161895A1 (en) | 2025-01-27 | 2026-07-30 | Tune Therapeutics, Inc. | Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| EP2566972B1 (en) | 2010-05-03 | 2020-01-15 | Sangamo Therapeutics, Inc. | Compositions for linking zinc finger modules |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| EP3443081A4 (en) * | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
| AU2019255789B2 (en) * | 2018-04-19 | 2025-11-20 | The Regents Of The University Of California | Compositions and methods for gene editing |
| AU2019282149B2 (en) | 2018-06-05 | 2025-08-21 | Life Edit Therapeutics, Inc. | RNA-guided nucleases and active fragments and variants thereof and methods of use |
| CN116234902A (zh) | 2020-05-04 | 2023-06-06 | 利兰·斯坦福青年大学托管委员会 | 用于激活和沉默基因表达的效应物结构域的生成、鉴定和表征的组合物、系统和方法 |
| EP4158009A4 (en) * | 2020-06-02 | 2024-10-02 | The Regents of the University of California | Compositions and methods for gene editing |
| AU2021409729A1 (en) * | 2020-12-22 | 2023-07-13 | Nchroma Bio, Inc. | Compositions and methods for epigenetic editing |
| EP4437092A1 (en) * | 2021-11-26 | 2024-10-02 | Epigenic Therapeutics Inc. | Method of modulating pcsk9 and uses thereof |
-
2023
- 2023-05-01 CN CN202380051043.XA patent/CN119836432A/zh active Pending
- 2023-05-01 AU AU2023265968A patent/AU2023265968A1/en active Pending
- 2023-05-01 WO PCT/US2023/066436 patent/WO2023215711A1/en not_active Ceased
- 2023-05-01 CA CA3251776A patent/CA3251776A1/en active Pending
- 2023-05-01 JP JP2024564785A patent/JP2025516294A/ja active Pending
- 2023-05-01 IL IL316722A patent/IL316722A/en unknown
- 2023-05-01 EP EP23729624.9A patent/EP4519293A1/en active Pending
- 2023-05-01 KR KR1020247039938A patent/KR20250060954A/ko active Pending
-
2024
- 2024-10-31 MX MX2024013483A patent/MX2024013483A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Loss of Sam50 in hepatocytes induces cardiolipin‐dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury | |
| JP2023145597A (ja) | Rnaを編集するための組成物および方法 | |
| Ford et al. | Protein transduction: an alternative to genetic intervention? | |
| Zahid et al. | Identification of a cardiac specific protein transduction domain by in vivo biopanning using a M13 phage peptide display library in mice | |
| Völkers et al. | PRAS40 prevents development of diabetic cardiomyopathy and improves hepatic insulin sensitivity in obesity | |
| US6468985B1 (en) | Retinoblastoma protein-interacting zinc finger proteins | |
| US20260091120A1 (en) | Cell-penetrating peptides | |
| Matsui et al. | Protein therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery | |
| US12268749B2 (en) | Cell-penetrating peptides | |
| US20060182736A1 (en) | Transducible dna-binding proteins | |
| US20180346531A1 (en) | Compositions and methods for delivering biotherapeutics | |
| Steinman et al. | Experimental encephalomyelitis at age 90, still relevant and elucidating how viruses trigger disease | |
| KR20220079524A (ko) | 접합체 및 이의 용도 | |
| US9474781B2 (en) | Method for inhibiting cell death during liver failure by administering a caspase recruitment domain | |
| DE69426121T2 (de) | Gen grb3-3, variante und ihre verwendungen | |
| JP2016516054A (ja) | コレステロール流出を刺激する、減少した毒性を有するペプチド | |
| EP2771367B1 (en) | Gigaxonin fusion protein and methods for treating giant axonal neuropathy | |
| JP5700409B2 (ja) | Hsp90を標的にした新規抗がんキメラペプチド | |
| JP2024533314A5 (cg-RX-API-DMAC7.html) | ||
| US6323335B1 (en) | Retinoblastoma protein-interacting zinc finger proteins | |
| Yang et al. | Cardiac fibroblasts-specific USP7 drives post-infarction cardiac fibrosis by deubiquitinating Krüppel-like factor 7 to promote myofibroblast activation | |
| US12404307B2 (en) | Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents | |
| US20230270887A1 (en) | Active delivery of nucleic acids and peptides, methods and uses | |
| JP2003530835A (ja) | 高トリグリセリド血症を誘発することなくコレステロールレベルを低下するための化合物と方法 | |
| US9993521B2 (en) | Modulation of scleraxis using a dominant negative scleraxis mutant with a basic DNA-binding domain deletion |